Evidence map›Paper›PMID 42156560›Full record

Trial reportCellular and molecular neurobiology2026

C1-esterase Inhibitor Treatment is Associated with Immune and Vascular Pathway Modulation in PASC with Neurological Symptoms: Longitudinal Plasma Proteomics.

Noga Orr, Maureen Collins, Shawn Novak, Isaac Melamed, Lawrence Steinman

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cellular and molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Noga OrrDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. ornoga@gmail.com.ORCID http://orcid.org/0000-0001-9631-3818
Maureen CollinsIMMUNOe Research Center, Centennial, CO, USA.
Shawn NovakIMMUNOe Research Center, Centennial, CO, USA.
Isaac MelamedIMMUNOe Research Center, Centennial, CO, USA.
Lawrence SteinmanDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-2437-2250

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-acute sequelae of SARS-CoV-2 infection (PASC), particularly neurological manifestations, remain a significant therapeutic challenge, likely driven by persistent inflammation, immune dysregulation, and endothelial dysfunction. In a randomized, double-blind, placebo-controlled crossover trial, 10 patients with post-COVID-19 neurological symptoms received C1-esterase inhibitor (C1-INH; RUCONEST

Indexed as

Complement C1 Inhibitor ProteinCOVID-19COVID-19 Drug TreatmentNervous System DiseasesProteomicsAdultCross-Over StudiesDouble-Blind MethodFemaleHumansLongitudinal StudiesMaleMiddle AgedPost-Acute COVID-19 SyndromeSARS-CoV-2Complement C1 Inhibitor ProteinC1-INHInflammationNeuroimmune homeostasisPlasma proteomicsPost-acute sequelae of SARS-CoV-2 infection (PASC)Randomized trial

Identifiers

PMID42156560
PMCPMC13357479

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.